Women’s Health / Cardiovascular Disease / Prevention

Cardiovascular Disease in Women: Comprehensive Guide to Sex-Specific Prevention and Risk Management

Creator: Dr. Joshua Lindsley
Published: 2026-02-23

Dr. Joshua Lindsley, DO | Last Updated: January 2026 | 24 min read

Key Takeaways

CVD is the leading cause of death in women — killing more women than all cancers combined — yet remains systematically underdiagnosed and undertreated
Pregnancy complications like preeclampsia confer 4× heart failure risk and 2× coronary disease risk that persists for decades
PCOS affects 1 in 8 women and increases cardiovascular event risk 1.5–2 fold; early menopause (<45) doubles CVD risk
Standard risk calculators (Framingham, QRISK) do not capture female-specific risk factors, leading to systematic underestimation
HRT timing matters: initiation before age 60 and within 10 years of menopause may be cardioprotective; transdermal estrogen is preferred

Summary

Cardiovascular disease (CVD) remains the leading cause of death in women worldwide, yet it is systematically understudied, underdiagnosed, and undertreated in female patients.¹ This disparity has resulted in women being disproportionately affected by CVD compared to men, with concerning trends showing increasing cardiovascular mortality in younger women.² While significant progress was made in reducing CVD deaths between 2000–2010, recent years have seen a reversal of these gains, particularly in middle-aged women (ages 45–64), who now represent a demographic of growing concern for heart disease mortality.¹

Women face unique cardiovascular risks related to their reproductive and hormonal biology that are not captured by traditional risk calculators.³ These include adverse pregnancy outcomes (preeclampsia, gestational diabetes), polycystic ovary syndrome (PCOS), early menopause, and the hormonal changes of the menopausal transition itself. Women who experience preeclampsia, for example, have a four-fold increased risk of heart failure (RR 4.19) and double the risk of coronary heart disease and stroke compared to women with uncomplicated pregnancies.⁴ These pregnancy-related cardiovascular risks manifest early and persist for decades.

Understanding these sex-specific risk factors provides a critical window for early intervention. The menopausal transition, in particular, represents a period of accelerated cardiovascular risk accumulation that warrants aggressive preventive measures. This guide examines the epidemiology of CVD in women, unique female risk factors, the role of hormones including hormone replacement therapy, and evidence-based prevention strategies tailored to women’s cardiovascular health across the lifespan.

CVD in Women at a Glance

Metric	Data
Leading cause of death in women	CVD (globally and in the US)
Annual CVD deaths in women (US)	~400,000
% of all female deaths from CVD	~1 in 5
Breast cancer deaths (comparison)	~43,000/year
Lifetime CVD risk for women	1 in 3

The Bottom Line

Cardiovascular disease in women requires a sex-specific approach that goes beyond traditional risk factor management. The female reproductive lifespan provides multiple opportunities for early identification of cardiovascular risk — from PCOS in young women, through pregnancy complications, to the menopausal transition. These windows of vulnerability are also windows of opportunity for intervention.

The disturbing reversal of progress in CVD mortality among women, particularly middle-aged women, reflects the growing epidemic of metabolic disease including obesity, diabetes, and metabolic syndrome. Over 90% of cardiovascular disease is preventable through modifiable risk factors, yet women continue to be underdiagnosed, underassessed, and undertreated. Standard risk calculators fail to capture uniquely female risk factors, leading to systematic underestimation of cardiovascular risk.

For women with histories of adverse pregnancy outcomes, PCOS, early menopause, or multiple traditional risk factors, proactive cardiovascular risk assessment and management is essential. The evidence supports early and aggressive intervention during the menopausal transition, potentially including hormone replacement therapy for symptomatic women without contraindications, initiated within the “window of opportunity” (age <60, within 10 years of menopause). Ultimately, comprehensive cardiovascular prevention in women requires attention to the complete reproductive and metabolic history, individualized risk assessment, and lifelong commitment to healthy behaviors combined with appropriate medical therapy when indicated.

Continue Reading This Evidence-Based Guide

Free access to 235+ health education guides from Highland Longevity

No spam. Unsubscribe anytime.

Epidemiology: CVD in Women

Historical Trends

Period	Trend in Women	Key Drivers
1987–2000	CVD mortality rising	Lack of awareness, treatment gaps
2000–2010	Significant decline	Increased awareness, statins, BP treatment
2010–Present	Decline stagnated/reversed	Obesity, diabetes, metabolic syndrome epidemic

Concerning Current Trends

The fastest-growing heart disease death rate is in middle-aged women (ages 45–64).

Age Group	Trend Since 2010	Clinical Significance
Women <65 years	+0.5% per year increase	Gap with cancer narrowing
Women 45–64	Fastest growing	May overtake cancer as #1 killer
Young women overall	Cardiovascular events rising	Early intervention critical

Sex Differences in CVD Presentation

Feature	Men	Women
Typical angina	Crushing chest pain	Less common
Atypical symptoms	Unusual	More common
Jaw/neck/back pain	Less common	More common
Nausea/fatigue	Less common	More common
Age at first MI	Earlier (50s–60s)	Later (60s–70s)
Post-MI mortality	Lower	Higher
Microvascular disease	Less common	More common

Traditional vs. Sex-Specific Risk Factors

Traditional Risk Factors (Affect Both Sexes)

Risk Factor	Notes for Women
Hypertension	Becomes more prevalent after menopause
Dyslipidemia	Lipid profile worsens after menopause
Diabetes	Confers 44–57% higher relative CHD risk in women vs. men⁸
Smoking	25% greater relative risk vs. men
Obesity	Central obesity particularly harmful
Physical inactivity	High prevalence in women
Family history	Important in both sexes

Female-Specific Risk Factors

Risk Factor	Associated CVD Risk Increase
Preeclampsia	2–4× lifetime CVD risk
Gestational diabetes	2× type 2 diabetes risk; elevated CVD
Preterm delivery	1.5–2× CVD risk
Pregnancy loss	Modestly elevated CVD risk
PCOS	2–2.5× CVD events
Early menopause (<45)	2× CVD risk
Premature menopause (<40)	Significantly elevated risk
Grand multiparity (5+ children)	Elevated CVD risk
Hysterectomy/oophorectomy	Risk depends on age and HRT use
Oral contraceptives	Small risk with certain formulations
Autoimmune diseases	More common in women; CVD risk

Critical Gap

Sex-specific risk factors are NOT included in standard cardiovascular risk calculators (QRISK, Framingham). This leads to systematic underestimation of CVD risk in women with histories of adverse pregnancy outcomes, PCOS, early menopause, or autoimmune disease.

Adverse Pregnancy Outcomes and CVD Risk

Preeclampsia⁴

Definition: Hypertensive disorder of pregnancy affecting up to 8% of pregnancies worldwide.

CVD Outcome	Risk Increase (RR)	Timeline
Heart failure	4.19 (95% CI: 2.09–8.38)	Decades
Coronary heart disease	2.50 (95% CI: 1.43–4.37)	Lifetime
Stroke	1.81 (95% CI: 1.29–2.55)	Within 10 years and beyond
CVD death	2.21 (95% CI: 1.83–2.66)	Lifetime
Hypertension	3–4×	Lifetime

Early vs. Late Preeclampsia

Type	Onset	Risk Profile
Early preeclampsia	<34 weeks	Higher cardiovascular risk
Late preeclampsia	>34 weeks	Elevated but lower than early
Severe preeclampsia	Any timing	Greatest long-term risk
Recurrent preeclampsia	Multiple pregnancies	Very high risk

Gestational Diabetes

Outcome	Risk	Notes
Type 2 diabetes	50% lifetime risk	Within 10–20 years
CVD	Elevated	Mediated through metabolic dysfunction
Metabolic syndrome	Elevated	Long-term risk

Other Adverse Pregnancy Outcomes

Outcome	CVD Risk Elevation
Preterm delivery (<37 weeks)	1.5–2×
Small for gestational age	Modest increase
Placental abruption	Elevated
Stillbirth	Elevated

Key Finding

Women with pregnancy complications can significantly lower their future CVD risk through healthy lifestyle behaviors and risk factor management. The risk can be reduced to levels comparable to women without pregnancy complications.

Recommended Surveillance After Preeclampsia

Annual blood pressure monitoring
Annual lipid panel
Annual glucose/HbA1c screening
Regular weight monitoring
Consider baseline echocardiogram for early/severe preeclampsia

Polycystic Ovary Syndrome (PCOS)⁵

Overview

Metric	Data
Prevalence	12% of women globally; 1 in 8 in US
Most common endocrinopathy	Yes (in reproductive-age women)
CVD event risk increase	1.5–2.0 fold (OR 1.66; 95% CI: 1.32–2.08)

PCOS and Metabolic Risk

Risk Factor	Prevalence in PCOS	Notes
Insulin resistance	50–70%	Core pathophysiology
Metabolic syndrome	30–40%	Higher than general population
Type 2 diabetes	2–4× increased risk	Often early onset
Dyslipidemia	Common	Low HDL, high triglycerides
Hypertension	Elevated risk	May be early onset
NAFLD/MASLD	40–55%	Linked to metabolic dysfunction
Obesity	40–80%	Central adiposity predominant

CVD Manifestations in PCOS

Finding	Evidence
Coronary artery calcium	Higher prevalence
Carotid intima-media thickness	Increased
Arterial stiffness	Present
Endothelial dysfunction	Documented
Ischemic heart disease	2× risk
Stroke	Elevated risk
Atrial fibrillation	Elevated risk

PCOS Phenotypes and CVD Risk

Phenotype	Characteristics	CVD Risk
Classic (hyperandrogenic)	Oligo/anovulation + hyperandrogenism	Greater liver fat, metabolic dysfunction
Ovulatory PCOS	Hyperandrogenism + polycystic ovaries	Moderate
Normoandrogenic PCOS	Oligo/anovulation + polycystic ovaries	Paradoxically higher CVD incidence

Management Approach

Intervention	Benefit
Lifestyle modification	Foundation of treatment
Weight loss (5–10%)	Improves all metabolic parameters
Metformin	Insulin sensitization
GLP-1 agonists	Emerging evidence for benefit
Hormonal contraceptives	Regulate cycles, may help some symptoms
Statins	Consider for dyslipidemia
Bariatric surgery	For severe obesity

2023 International PCOS Guideline Recommendations

Recognize PCOS as a significant risk factor for CVD morbidity. Comprehensive cardiovascular risk assessment is recommended in all women with PCOS, with early intervention to mitigate CVD burden and address both reproductive and cardiometabolic dimensions.

Menopause and Cardiovascular Risk

The Menopausal Transition

Term	Definition
Natural menopause	Average age 51 (range 45–55)
Early menopause	Age <45 (affects ~10% of women)
Premature menopause/POI	Age <40 (affects ~1% of women)
Surgical menopause	Bilateral oophorectomy

CVD Risk by Menopause Timing⁶

Menopause Type	CVD Risk Impact
Age-appropriate (50–51)	Baseline postmenopausal risk
Early (40–44)	30% increased risk (HR 1.30; 95% CI: 1.22–1.39)
Premature (<40)	55% increased risk (HR 1.55; 95% CI: 1.38–1.73)
Premature, CVD before age 60	88% increased risk (HR 1.88; 95% CI: 1.62–2.20)
Surgical (bilateral oophorectomy)	Depends on age and HRT use

Mechanisms of Increased Risk

Mechanism	Effect
Estrogen loss	Endothelial dysfunction, vascular stiffness
Lipid changes	Increased LDL, decreased HDL
Fat redistribution	Increased visceral adiposity
Glucose metabolism	Insulin resistance develops
Inflammation	Chronic low-grade inflammation
RAAS activation	Long-term vascular damage

Metabolic Changes at Menopause

Parameter	Change
Total cholesterol	Increases
LDL cholesterol	Increases 10–15%
HDL cholesterol	May decrease
Triglycerides	Increase
apoB	Increases
Lipoprotein(a)	May increase
Fasting glucose	Increases
Weight	Increases (average 2–5 kg)
Body fat distribution	Shifts to central/visceral
Blood pressure	Increases

Vasomotor Symptoms and CVD

Finding	Clinical Significance
Hot flashes/night sweats	Associated with increased CVD risk
Sleep disruption	Contributes to poor cardiovascular health
Persistent VMS	May indicate higher CVD risk
Early-onset VMS	May predict future cardiovascular events

Hormone Replacement Therapy: The Timing Hypothesis⁷

The Evolution of HRT Understanding

Era	Understanding
Pre-2002	HRT assumed cardioprotective
WHI 2002	HRT showed increased CVD events (in older women, mean age 63)
Post-WHI	Re-analysis revealed timing matters
Current	“Timing hypothesis” and “healthy endothelium hypothesis”

The Timing Hypothesis Explained

Core Concept: The effects of HRT on cardiovascular health depend critically on WHEN it is initiated relative to menopause onset.

Initiation Timing	CVD Effect	Mechanism
Early (<60 years, within 10 years of menopause)	Potentially beneficial	Acts on healthy endothelium
Late (>60 years, >10 years post-menopause)	Potentially harmful	May destabilize existing plaques

Evidence Supporting Timing Hypothesis

Study/Evidence	Findings
ELITE Trial	Earlier initiation = better carotid IMT outcomes
KEEPS Trial	Early HRT showed no adverse cardiovascular effects
Danish Osteoporosis Study	Early HRT reduced MI and heart failure
Meta-analyses	Younger initiation reduces mortality and cardiac events

2024 Research Updates

Finding	Clinical Implication
Transdermal estrogen	Lower cardiovascular risk than oral
CEE favorable lipid effects	HDL +13%, LDL −11%
Younger initiators	No increased CHD or mortality risk
Stroke risk	May persist even with early initiation

HRT Decision Framework

Candidate	Recommendation	Notes
Symptomatic, <60, within 10 years of menopause, no CVD	Generally appropriate	Transdermal preferred
Symptomatic, 60–70, low CVD risk	Individual decision	Lower doses, transdermal
Known CVD	Generally not recommended	Alternative treatments
High CVD risk (ASCVD >10%)	Caution	Shared decision-making
>70 years or >20 years post-menopause	Generally avoid initiating	Continuation may differ

HRT Formulation Considerations

Type	CV Risk Profile
Transdermal estrogen	Preferred; lower VTE, stroke risk
Oral estrogen	Higher VTE, stroke risk
Micronized progesterone	May be preferable for breast/CV safety
Synthetic progestins	Variable risk profiles

Lipid Management in Women

Lipid Changes Across Female Lifespan

Life Stage	Typical Lipid Profile
Premenopausal	Generally favorable; higher HDL than men
Pregnancy	Physiological increases in all lipids
Postmenopausal	LDL increases; HDL may decrease
Elderly	May approach or exceed male levels

ApoB as the Causal Agent

Key Point: ApoB-containing lipoproteins (LDL, VLDL, Lp(a)) are the causal agents of atherosclerotic CVD. This is true in both sexes, but women are often undertreated.

Biomarker	Target for Prevention	Notes
apoB	<90 mg/dL (moderate risk), <80 mg/dL (high risk)	More accurate than LDL-C
LDL-C	<100 mg/dL (moderate), <70 mg/dL (high risk)	May underestimate risk
Non-HDL-C	<130 mg/dL (moderate), <100 mg/dL (high risk)	Better than LDL-C alone
Lp(a)	Know your level	Genetic; limited treatment

Undertreatment of Women

Finding	Data
Women less likely to be prescribed statins	Despite equivalent benefit
Women with FH undertreated	Lifetime risk greatly elevated
Women less likely to reach LDL targets	Treatment intensity lower
Statin discontinuation	Higher in women

Familial Hypercholesterolemia in Women

Issue	Clinical Importance
Often diagnosed later	After pregnancy or menopause
Statin-free during pregnancy	LDL rises during fertile years
Cumulative LDL exposure	Higher lifetime exposure
Earlier intervention needed	Should start treatment before pregnancy years if possible

Pharmacological Prevention

Statins in Women

Evidence	Finding
Primary prevention	Effective, though some trials underpowered for women
Secondary prevention	Clear benefit
Meta-analyses	Similar relative risk reduction to men
Absolute risk reduction	May be lower due to lower baseline risk (premenopausal)

Statin Considerations

Issue	Guidance
Side effects	May be reported more frequently by women
Pregnancy	Contraindicated; stop 1–3 months before conception
Breastfeeding	Generally avoided
Postmenopausal	No different efficacy vs. men

PCSK9 Inhibitors

Drug	Benefit in Women
Evolocumab	Effective; similar benefit to men
Alirocumab	Effective; similar benefit to men
Inclisiran	Emerging data

GLP-1 Agonists

Finding	Significance
Weight loss	Benefits metabolic profile
CV outcome reduction	Demonstrated in trials
PCOS	Emerging evidence for benefit
Postmenopausal metabolic syndrome	May be particularly helpful

Lp(a) Management

Current Status	Details
Elevated Lp(a)	~20% of population
Genetic determination	~90% heritable
Current treatment	No approved Lp(a)-lowering drugs
Clinical trials	Pelacarsen, olpasiran in trials
Risk enhancer	Reclassifies intermediate-risk patients

Lifestyle Interventions

Impact of Lifestyle on CVD Risk in Women

Intervention	CVD Risk Reduction
Optimal lifestyle factors	Up to 80% reduction possible
Physical activity (150 min/week)	30–40% reduction
Mediterranean diet	25–30% reduction
Non-smoking	50%+ reduction vs. smokers
Healthy weight	Significant reduction
Stress management	Moderate reduction
Adequate sleep	Contributes to overall health

Exercise Recommendations

Parameter	Recommendation
Aerobic exercise	150+ min/week moderate OR 75+ min vigorous
Resistance training	2+ days/week
Zone 2 training	Foundation of cardio program
High-intensity intervals	1–2×/week
Daily movement	Avoid prolonged sitting

Dietary Considerations

Pattern	Evidence
Mediterranean diet	Strong evidence for CVD reduction
DASH diet	Effective for blood pressure
Plant-forward eating	Generally beneficial
Limit ultra-processed foods	Reduces metabolic risk
Moderate alcohol	Complex; no longer recommended to start

Stress and Mental Health

Factor	CVD Impact
Chronic stress	Elevates CVD risk
Depression	Independent risk factor
Anxiety	May increase risk
Social isolation	Significant risk factor
Sleep deprivation	Increases metabolic risk

Special Considerations for Women

Oral Contraceptives

Consideration	Guidance
Modern low-dose pills	Low absolute CVD risk in healthy women
Smoking + OCP	Contraindicated over age 35
Hypertension + OCP	Relative contraindication
Migraine with aura + OCP	Contraindicated (stroke risk)
Age >35 with risk factors	Consider non-estrogen alternatives

Autoimmune Disease

Condition	CVD Risk
Rheumatoid arthritis	1.5–2× increased
Systemic lupus erythematosus	2–10× increased
Psoriasis/psoriatic arthritis	Elevated
Inflammatory bowel disease	Modestly elevated

Cancer Survivorship

Treatment	CV Consideration
Chest radiation	Accelerated coronary disease
Anthracyclines	Cardiomyopathy risk
HER2-targeted therapy	Cardiac dysfunction
Aromatase inhibitors	Lipid effects
Early menopause (from treatment)	Accelerated CVD risk

Pregnancy Planning with CVD Risk Factors

Situation	Approach
FH	Optimize LDL before and after pregnancy; stop statins
Hypertension	Blood pressure optimization
Diabetes	Glucose control; switch to insulin if needed
Prior preeclampsia	Low-dose aspirin for prevention
High BMI	Preconception weight loss if possible

Clinical Action Framework

Risk Assessment by Life Stage

Life Stage	Key Actions
Adolescence/Young Adult	Identify FH, PCOS; establish healthy behaviors
Preconception	Optimize modifiable risk factors
Pregnancy	Monitor for hypertensive disorders, GDM
Postpartum	Screen for persistent risk factors
Perimenopausal	Aggressive risk factor management
Postmenopausal	Consider HRT timing; lipid management
Elderly	Continue prevention; avoid overtreatment

Screening Schedule for Women

Test	Frequency	Notes
Blood pressure	At every healthcare visit	More frequent if elevated
Lipid panel	Every 4–6 years (low risk)	Annual if risk factors
Glucose/HbA1c	Every 3 years (age 45+)	Annual if prediabetes
Weight/BMI	Every visit	With waist circumference
Lp(a)	Once in lifetime	Earlier if family history
apoB	Consider for risk refinement	Especially if discordant LDL
CAC score	Individual decision	Risk reclassification

When to Refer to Cardiology/Preventive Cardiology

Scenario	Referral Indication
Elevated Lp(a) with CVD concern	Specialist guidance
FH confirmed or suspected	Lipid specialist
Multiple adverse pregnancy outcomes	Cardio-obstetrics
Premature menopause	CV risk assessment
Known CVD	Secondary prevention
Treatment-resistant risk factors	Specialist management
Young onset CVD	Comprehensive workup

Summary of Key Numbers to Know

Parameter	Target/Threshold
Blood pressure	<120/80 mmHg optimal
LDL-C (low risk)	<100 mg/dL
LDL-C (high risk)	<70 mg/dL
apoB (high risk)	<80 mg/dL
HbA1c	<5.7% (normal)
BMI	18.5–24.9 kg/m²
Waist circumference	<35 inches (women)
Lp(a)	Know your level (<50 nmol/L desirable)

Key Clinical Pearls

Epidemiology and Awareness

CVD kills more women than all cancers combined, yet women often fear breast cancer more
Middle-aged women (45–64) are the fastest-growing demographic for CVD mortality
Women present with different symptoms than men and are more likely to have atypical presentations

Sex-Specific Risk Factors

Pregnancy is a cardiovascular “stress test” — complications signal future risk
Preeclampsia confers 4× heart failure risk and 2× coronary disease risk
PCOS affects 1 in 8 women and increases CVD risk 2–2.5 fold
Early menopause (<45) doubles cardiovascular risk

Prevention and Treatment

Standard risk calculators underestimate risk in women with sex-specific factors
Women are undertreated with statins despite equivalent benefit
HRT timing matters: early initiation (<60, within 10 years of menopause) may be beneficial
Transdermal estrogen is preferred over oral for cardiovascular safety
Lifestyle modification can reduce CVD risk by up to 80%

Action Items

Ask about pregnancy history in all cardiovascular risk assessments
Screen women with adverse pregnancy outcomes annually for CV risk factors
Recognize PCOS as a cardiovascular risk enhancer requiring early intervention
Consider aggressive preventive measures at the menopausal transition

Key Studies & Data

Finding	Result	Significance
Preeclampsia → heart failure⁴	RR 4.19 (95% CI: 2.09–8.38)	Meta-analysis of 22 studies, 6.4 million women
Preeclampsia → CHD⁴	RR 2.50 (95% CI: 1.43–4.37)	Independent risk after adjusting for confounders
PCOS → CVD events⁵	OR 1.66 (95% CI: 1.32–2.08)	2023 guideline update, 1 million women pooled
Early menopause (<45) → CVD⁶	HR 1.30 (95% CI: 1.22–1.39)	InterLACE pooled analysis, 15 cohorts
Premature menopause (<40) → CVD⁶	HR 1.55 (95% CI: 1.38–1.73)	Risk greatest before age 60
Diabetes → CHD (women vs. men)⁸	44–57% higher relative risk	Meta-analysis of 37 cohort studies
HRT timing hypothesis⁷	Reduced MI/mortality age 50–59	WHI age-stratified analysis

Additional Considerations

Study Limitations

WHI age bias: Original WHI enrolled women mean age 63; findings may not apply to younger symptomatic women initiating HRT.
Observational pregnancy data: Preeclampsia-CVD associations are largely observational; causality cannot be definitively established.
Risk calculator gaps: Framingham/QRISK were validated primarily in male populations; female-specific calibration is limited.
PCOS heterogeneity: Different PCOS phenotypes have varying metabolic profiles; pooled risk estimates may obscure phenotype-specific risks.

Conflicting Evidence

HRT cardiovascular effects: Some analyses suggest no cardioprotection even with early initiation; KEEPS showed no significant cardiovascular benefit.
PCOS mortality: Meta-analyses show increased CVD incidence but not significantly increased cardiovascular mortality.
Early menopause causality: Association vs. causation remains debated — early menopause may be a marker of underlying disease rather than direct cause.

Individual Variation

Genetic susceptibility: FH, Lp(a) levels, and other genetic factors modify baseline risk independent of sex-specific factors.
Ethnicity: CVD risk varies significantly across racial/ethnic groups; Black women have highest CVD mortality.
Socioeconomic factors: Access to care, health literacy, and stress exposure modify risk substantially.
Comorbidities: Autoimmune conditions (RA, SLE) common in women add independent CVD risk.

Safety Notes

HRT contraindications: Known CVD, prior VTE, active liver disease, unexplained vaginal bleeding.
Statin pregnancy: Statins are contraindicated in pregnancy; women of reproductive age need counseling.
Aspirin: Low-dose aspirin for primary prevention no longer routinely recommended due to bleeding risk.
OCP + smoking: Combined oral contraceptives contraindicated in smokers over age 35.

Evidence Gaps

Long-term PCOS outcomes: Need for prospective studies following PCOS patients into late adulthood.
Optimal HRT formulations: Limited head-to-head trials comparing transdermal vs. oral, different progestins.
Pregnancy complications interventions: Unclear if treating risk factors post-preeclampsia actually reduces future CVD events.

Recent Developments

2023 International PCOS Guideline: Now explicitly recognizes PCOS as a CVD risk factor requiring comprehensive assessment.⁵
2024 AHA/ASA Stroke Prevention Guideline: Updated sex-specific recommendations for MHT and stroke prevention.
Lp(a)-lowering trials: Pelacarsen and olpasiran trials ongoing; potential benefit for high-Lp(a) women.
2024 WHI biomarker analysis: New data on durable cardiovascular biomarker changes post-MHT.

References

Mosca, L., Benjamin, E. J., Berra, K., et al. (2011). Effectiveness-based guidelines for the prevention of cardiovascular disease in women—2011 update: A guideline from the American Heart Association. Circulation, 123(11), 1243–1262.
American Heart Association. (2024). 2024 Heart Disease and Stroke Statistics: A Report of US and Global Data. Circulation, 149(8), e347–e913.
El Khoudary, S. R., Aggarwal, B., Beckie, T. M., et al. (2020). Menopause transition and cardiovascular disease risk: Implications for timing of early prevention: A scientific statement from the American Heart Association. Circulation, 142(25), e506–e532.
Wu, P., Haththotuwa, R., Kwok, C. S., et al. (2017). Preeclampsia and future cardiovascular health: A systematic review and meta-analysis. Circulation: Cardiovascular Quality and Outcomes, 10(3), e003497.
Wekker, V., et al. (2024). 2023 International Evidence-Based Polycystic Ovary Syndrome Guideline Update: Insights from a systematic review and meta-analysis on elevated clinical cardiovascular disease in polycystic ovary syndrome. Journal of the American Heart Association, 13(16), e033572.
Zhu, D., Chung, H. F., Dobson, A. J., et al. (2019). Age at natural menopause and risk of incident cardiovascular disease: A pooled analysis of individual patient data. The Lancet Public Health, 4(11), e553–e564.
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., et al. (2013). Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA, 310(13), 1353–1368.
Huxley, R., Barzi, F., & Woodward, M. (2006). Excess risk of fatal coronary heart disease associated with diabetes in men and women: Meta-analysis of 37 prospective cohort studies. BMJ, 332(7533), 73–78.

Medical Disclaimer: This educational brief is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before making decisions about cardiovascular prevention or hormone therapy. Individual results may vary. The information presented reflects current research as of January 2026 and may be updated as new evidence becomes available.